Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation

Biochemical and Biophysical Research Communications

Volumn 398, Issue 2, 2010, Pages 326-330

  Matsui, Takanori ^a   Yamagishi, Sho ichi ^a   Takeuchi, Masayoshi ^b   Ueda, Seiji ^a   Fukami, Kei ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

AGEs; Diabetic nephropathy; Nifedipine; PPAR ; RAGE

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMLODIPINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; NIFEDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR MEMBRANE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; TRANSCRIPTION INITIATION;

ANILIDES; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; DIABETIC NEPHROPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY TUBULES; NIFEDIPINE; OXIDATIVE STRESS; PPAR GAMMA; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC;

EID: 77955052182     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.093     Document Type: Article

References (29)

1. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy, its therapeutic intervention. Curr. Drug Targets 2007, 8:952-959.
2. Taft J.L., Nolan C.J., Yeung S.P., Hewitson T.D., Martin F.I. Clinical, histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994, 43:1046-1051.
3. Ziyadeh F.N., Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int. 1991, 39:464-475.
4. Vlassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994, 70:138-151.
5. Rahbar S. The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann. NY Acad. Sci. USA 2005, 1043:9-19.
6. Soldatos G., Cooper M.E. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res. Clin. Pract. 2008, 82:S75-S79.
7. D'Agati V., Yan S.F., Ramasamy R., Schmidt A.M. RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol. Metab. 2010, 21:50-56.
8. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 2005, 11:2279-2299.
9. Yamagishi S., Nakamura K., Matsui T., Ueda S., Fukami K., Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Exp. Opin. Invest. Drugs 2008, 17:983-996.
10. Yamagishi S., Nakamura K., Matsui T., Noda Y., Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr. Pharm. Des. 2008, 14:487-495.
11. Fukami K., Yamagishi S., Ueda S., Okuda S. Role of AGEs in diabetic nephropathy. Curr. Pharm. Des. 2008, 14:946-952.
12. Mancia G. Optimal control of blood pressure in patients with diabetes reduces the incidence of macro and microvascular events. J. Hypertens. Suppl. 2007, 1:S7-S12.
13. Barit D., Cooper M.E. Diabetic patients and kidney protection: an attainable target. J. Hypertens. Suppl. 2008, 26:S3-S7.
14. Matsui T., Yamagishi S., Nakamura K., Inoue H., Takeuchi M. Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells. J. Int. Med. Res. 2007, 35:107-112.
15. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem. Biophys. Res. Commun. 2009, 385:269-272.
16. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem. 2006, 281:20213-20220.
17. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., Makita Z. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem. 2002, 277:20309-20315.
18. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis, induce TGF-beta overexpression in proximal tubular cells. Kidney Int. 2003, 63:464-473.
19. Y. Ide, T. Matsui, Y. Ishibashi, M. Takeuchi, S. Yamagishi, Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation, Microvasc. Res. doi:10.1016/j.mvr.2010.03.015.
20. Yamagishi S., Matsui T., Nakamura K., Takeuchi M., Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Protein Pept. Lett. 2008, 15:850-853.
21. Matsui T., Nakamura K., Takeuchi M., Yamagishi S. Telmisartan blocks advanced glycation end product (AGE)-induced plasminogen activator inhibitor-1 (PAI-1) gene expression in endothelial cells via activation of peroxisome proliferator-activated receptor-g (PPAR-γ). Lett. Drug Des. Dis. 2008, 5:477-480.
22. Cooper M.E. Interaction of metabolic, haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001, 44:1957-1972.
23. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Tesch G.H. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J. Am. Soc. Nephrol. 2005, 16:1711-1722.
24. Chen S., Jim B., Ziyadeh F.N. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin. Nephrol. 2003, 23:532-543.
25. Baba S. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res. Clin. Prac. 2001, 54:191-201. J-MIND Study Group.
26. Takeuchi M., Makita Z., Yanagisawa K., Kameda K., Koike T. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 1999, 5:393-405.
27. Miura J., Yamagishi S., Uchigata Y., Takeuchi M., Yamamoto H., Makita Z., Iwamoto Y. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J. Diabetes Compl. 2003, 17:16-21.
28. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006, 49:3094-3099.
29. Dietz J.D., Du S., Bolten C.W., Payne M.A., Xia C., Blinn J.R., Funder J.W., Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008, 51:742-748.